Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges

Papers of special note have been highlighted as: • of interest; •• of considerable interest

Reference

• 1. Clark BZ, Onisko A, Assylbekova B et al. Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity. Mod. Pathol. 32(3), 354–366 (2019).
  MedlineGoogle Scholar
• 2. Mahvi DA, Liu R, Grinstaff MW et al. Local cancer recurrence: the realities, challenges, and opportunities for new therapies. CA Cancer J. Clin. 68(6), 488–505 (2018).
  MedlineGoogle Scholar
• 3. Parada H Jr, Sun X, Tse CK et al. Lifestyle patterns and survival following breast cancer in the Carolina Breast Cancer Study. Epidemiology 30(1), 83–92 (2019).
  MedlineGoogle Scholar
• 4. Cain EH, Saha A, Harowicz MR et al. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. Breast Cancer Res. Treat. 173(2), 455–463 (2019).
  Medline CASGoogle Scholar
• 5. Rizwanullah M, Ahmad MZ, Ghoneim MM et al. Receptor-mediated targeted delivery of surface-modifiednanomedicine in breast cancer: recent update and challenges. Pharmaceutics 13(12), 2039 (2021). •• Excellent review article summarizing the receptor mediated delivery of nanomedicine in breast cancer.
  Medline CASGoogle Scholar
• 6. Inic Z, Zegarac M, Inic M et al. Difference between luminal a and luminal b subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information. Clin. Med. Insights Oncol. 8, 107–111 (2014).
  Medline CASGoogle Scholar
• 7. Fragomeni SM, Sciallis A, Jeruss JS. Molecular subtypes and local-regional control of breast cancer. Surg. Oncol. Clin. N Am 27(1), 95–120 (2018).
  MedlineGoogle Scholar
• 8. Ahmad MZ, Ahmad J, Alasmary MY et al. Emerging advances in cationic liposomal cancer nanovaccines: opportunities and challenges. Immunotherapy 13(6), 491–507 (2021). •• Review article dealing with the cationic lipsomal cancer nanovaccines.
  CASGoogle Scholar
• 9. Ahmad MZ, Ahmad J, Haque A et al. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges. Expert Rev. Vaccines 19(11), 1053–1071 (2020).
  Medline CASGoogle Scholar
• 10. Coulie PG, Van Den Eynde BJ, Van Der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14(2), 135–146 (2014).
  Medline CASGoogle Scholar
• 11. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 541(7637), 321–330 (2017).
  Medline CASGoogle Scholar
• 12. Hewitt EW. The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 110(2), 163–169 (2003).
  Medline CASGoogle Scholar
• 13. Raval RR, Sharabi AB, Walker AJ et al. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J. Immunother. Cancer 2, 14 (2014).
  MedlineGoogle Scholar
• 14. Tan TJ, Chan JJ, Kamis S, Dent RA. What is the role of immunotherapy in breast cancer? Chinese Clin. Oncol. 7(2), 13 (2018).
  MedlineGoogle Scholar
• 15. Shao K, Singha S, Clemente-Casares X et al. Nanoparticle-based immunotherapy for cancer. ACS Nano 9(1), 16–30 (2015).
  Medline CASGoogle Scholar
• 16. De Melo Gagliato D, Buzaid AC, Perez-Garcia J, Cortes J. Immunotherapy in breast cancer: current practice and clinical challenges. BioDrugs 34(5), 611–623 (2020).
  MedlineGoogle Scholar
• 17. Goff SL, Danforth DN. The role of immune cells in breast tissue and immunotherapy for the treatment of breast cancer. Clin. Breast Cancer 21(1), e63–e73 (2021).
  Medline CASGoogle Scholar
• 18. Mina LA, Lim S, Bahadur SW, Firoz AT. Immunotherapy for the treatment of breast cancer: emerging new data. Breast Cancer 11, 321–328 (2019).
  Medline CASGoogle Scholar
• 19. Underwood JC. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br. J. Cancer 30(6), 538–548 (1974).
  Medline CASGoogle Scholar
• 20. Aaltomaa S, Lipponen P, Eskelinen M et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur. J. Cancer 28a(4–5), 859–864 (1992).
  Medline CASGoogle Scholar
• 21. Chin Y, Janseens J, Vandepitte J et al. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res. 12(5), 1463–1466 (1992).
  Medline CASGoogle Scholar
• 22. Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLOS ONE 9(2), e88557 (2014).
  MedlineGoogle Scholar
• 23. Sabatier R, Finetti P, Mamessier E et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 6(7), 5449–5464 (2015).
  MedlineGoogle Scholar
• 24. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8(3), 239–245 (2007).
  Medline CASGoogle Scholar
• 25. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am. J. Cancer Res. 10(3), 727–742 (2020).
  Medline CASGoogle Scholar
• 26. Yu LY, Tang J, Zhang CM et al. New immunotherapy strategies in breast cancer. Int. J. Environ. Res. Public Health 14(1), 68 (2017).
  Google Scholar
• 27. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol. Med. 21(1), 24–33 (2015).
  Medline CASGoogle Scholar
• 28. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1), 1–10 (2013).
  MedlineGoogle Scholar
• 29. Shi Y, Lammers T. Combining nanomedicine and immunotherapy. Acc. Chem. Res. 52(6), 1543–1554 (2019).
  Medline CASGoogle Scholar
• 30. Okazaki T, Chikuma S, Iwai Y et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14(12), 1212–1218 (2013).
  Medline CASGoogle Scholar
• 31. Basu A, Ramamoorthi G, Jia Y et al. Immunotherapy in breast cancer: current status and future directions. Adv. Cancer Res. 143, 295–349 (2019).
  MedlineGoogle Scholar
• 32. Li Y, Miao W, He D et al. Recent progress on immunotherapy for breast cancer: tumor microenvironment, nanotechnology and more. Front. Bioeng. Biotechnol. 9, 680315 (2021).
  MedlineGoogle Scholar
• 33. Azvolinsky A. What is tumor mutational burden? Cancer Today (2020). www.cancertodaymag.org/Pages/cancer-talk/What-Is-Tumor-Mutational-Burden.aspx
  Google Scholar
• 34. Mariathasan S, Turley SJ, Nickles D et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693), 544–548 (2018).
  Medline CASGoogle Scholar
• 35. Shao C, Li G, Huang L et al. Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. JAMA Netw. Open 3(10), e2025109 (2020).
  MedlineGoogle Scholar
• 36. Yarchoan M, Albacker LA, Hopkins AC et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4(6), e126908 (2019).
  MedlineGoogle Scholar
• 37. Rizvi NA, Cho BC, Reinmuth N et al. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Ann. Oncol. 29, x40–x41 (2018).
  Google Scholar
• 38. Danaher P, Warren S, Lu R et al. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J. Immunother. Cancer 6(1), 63 (2018).
  MedlineGoogle Scholar
• 39. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 348(6230), 69–74 (2015).
  Medline CASGoogle Scholar
• 40. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 500(7463), 415–421 (2013).
  Medline CASGoogle Scholar
• 41. National Cancer Institute. Definition of TIL. NCI Dictionary of Cancer Terms (2022). www.cancer.gov/publications/dictionaries/cancer-terms/def/til
  Google Scholar
• 42. Basu A, Ramamoorthi G, Jia Y et al. Chapter Six: Immunotherapy in breast cancer: current status and future directions. In: Advances in Cancer Research Wang X-YFisher PB (Eds). Academic Press, MA, USA, 295–349 (2019).
  Google Scholar
• 43. Ruan M, Tian T, Rao J et al. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers. Diagn. Pathol. 13(1), 66 (2018).
  MedlineGoogle Scholar
• 44. Ravelli A, Roviello G, Cretella D et al. Tumor-infiltrating lymphocytes and breast cancer: beyond the prognostic and predictive utility. Tumour Biol. 39(4), 1010428317695023 (2017).
  Google Scholar
• 45. Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol. 2(10), 1354–1360 (2016).
  MedlineGoogle Scholar
• 46. Denkert C, Von Minckwitz G, Darb-Esfahani S et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19(1), 40–50 (2018).
  MedlineGoogle Scholar
• 47. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25(8), 1544–1550 (2014).
  Medline CASGoogle Scholar
• 48. Salgado R, Denkert C, Campbell C et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial. JAMA Oncol. 1(4), 448–454 (2015).
  MedlineGoogle Scholar
• 49. Perez EA, Ballman KV, Tenner KS et al. Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol. 2(1), 56–64 (2016).
  MedlineGoogle Scholar
• 50. Luen SJ, Salgado R, Fox S et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 18(1), 52–62 (2017).
  Medline CASGoogle Scholar
• 51. Gentles AJ, Newman AM, Liu CL et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21(8), 938–945 (2015).
  Medline CASGoogle Scholar
• 52. Li W, Wei H, Li H, Gao J et al. Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. Nanomedicine 9(16), 2587–2605 (2014).
  CASGoogle Scholar
• 53. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991–998 (2002).
  Medline CASGoogle Scholar
• 54. Hashemzadeh N, Dolatkhah M, Adibkia K et al. Recent advances in breast cancer immunotherapy: the promising impact of nanomedicines. Life Sci. 271, 119110 (2021).
  Medline CASGoogle Scholar
• 55. Matthaiou EI, Barar J, Sandaltzopoulos R et al. Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. Int. J. Nanomedicine 9, 1855–1870 (2014).
  MedlineGoogle Scholar
• 56. Hashemzadeh N, Dolatkhah M, Aghanejad A et al. Folate receptor-mediated delivery of 1-MDT-loaded mesoporous silica magnetic nanoparticles to target breast cancer cells. Nanomedicine 16(24), 2137–2154 (2021).
  CASGoogle Scholar
• 57. Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nat. Rev. Cancer 19(10), 587–602 (2019).
  Medline CASGoogle Scholar
• 58. Yu HJ, De Geest BG. Nanomedicine and cancer immunotherapy. Acta Pharmacol. Sinica 41(7), 879–880 (2020).
  Medline CASGoogle Scholar
• 59. Ahmad MZ, Akhter S, Mohsin N et al. Transformation of curcumin from food additive to multifunctional medicine: nanotechnology bridging the gap. Curr. Drug Discov. Technol. 11(3), 197–213 (2014).
  Medline CASGoogle Scholar
• 60. Ahmad MZ, Akhter S, Rahman Z et al. Nanometric gold in cancer nanotechnology: current status and future prospect. J. Pharm. Pharmacol. 65(5), 634–651 (2013).
  Medline CASGoogle Scholar
• 61. Ahmad MZ, Alkahtani SA, Akhter S et al. Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art. J. Drug Target. 24(4), 273–293 (2016).
  Medline CASGoogle Scholar
• 62. Ahmad MZ, Rizwanullah M, Ahmad J et al. Progress in nanomedicine-based drug delivery in designing of chitosan nanoparticles for cancer therapy. Int. J. Polym. Mater. Polym. Biomater. 71(8), 602–623 (2021).
  Google Scholar
• 63. Akhter S, Ahmad Z, Singh A et al. Cancer targeted metallic nanoparticle: targeting overview, recent advancement and toxicity concern. Curr. Pharm. Des. 17(18), 1834–1850 (2011).
  Medline CASGoogle Scholar
• 64. Algahtani MS, Ahmad MZ, Nourein IH, Ahmad J. Co-delivery of imiquimod and curcumin by nanoemugel for improved topical delivery and reduced psoriasis-like skin lesions. Biomolecules 10(7), 968 (2020).
  CASGoogle Scholar
• 65. Algahtani MS, Ahmad MZ, Shaikh IA et al. Thymoquinone loaded topical nanoemulgel for wound healing: formulation design and in-vivo evaluation. Molecules 26(13), 3863 (2021).
  Medline CASGoogle Scholar
• 66. Algahtani MS, Ahmad MZ, Ahmad J. Nanoemulsion loaded polymeric hydrogel for topical delivery of curcumin in psoriasis. J. Drug Deliv. Sci. Technol. 59, 101847 (2020).
  CASGoogle Scholar
• 67. Fernandez-Fernandez A, Manchanda R, Mcgoron AJ. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl. Biochem. Biotechnol. 165(7–8), 1628–1651 (2011).
  Medline CASGoogle Scholar
• 68. Ahmad MZ, Akhter S, Jain GK et al. Metallic nanoparticles: technology overview & drug delivery applications in oncology. Expert Opin. Drug Deliv. 7(8), 927–942 (2010).
  Medline CASGoogle Scholar
• 69. Gong N, Zhang Y, Zhang Z, Li X, Liang XJ. Functional nanomaterials optimized to circumvent tumor immunological tolerance. Adv. Functional Materials 29(3), 1806087 (2019).
  Google Scholar
• 70. Huang P, Wang X, Liang X et al. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. Acta Biomater 85, 1–26 (2019).
  Medline CASGoogle Scholar
• 71. Park YM, Lee SJ, Kim YS et al. Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Netw. 13(5), 177–183 (2013).
  MedlineGoogle Scholar
• 72. Fu B, Huang X, Deng J et al. Application of multifunctional nanomaterials in cancer vaccines (Review). Oncol. Rep. 39(3), 893–900 (2018).
  Medline CASGoogle Scholar
• 73. Yu X, Dai Y, Zhao Y et al. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. Nat. Commun. 11(1), 1110 (2020).
  Medline CASGoogle Scholar
• 74. Kumar S, Anselmo AC, Banerjee A et al. Shape and size-dependent immune response to antigen-carrying nanoparticles. J. Control ReL. 220(Pt A), 141–148 (2015).
  Medline CASGoogle Scholar
• 75. Grimaldi AM, Incoronato M, Salvatore M, Soricelli A. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics. Nanomedicine 12(19), 2349–2365 (2017). • Nanomedicine-based cancer immunotherapy and immunodiagnostic.
  CASGoogle Scholar
• 76. Vangijzegem T, Stanicki D, Laurent S. Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. Expert Opin. Drug Deliv. 16(1), 69–78 (2019).
  Medline CASGoogle Scholar
• 77. Ahmad MZ, Ahmad J, Zafar S et al. Omega-3 fatty acids as adjunctive therapeutics: prospective of nanoparticles in its formulation development. Ther. Deliv. 11(1), 851–868 (2020).
  Medline CASGoogle Scholar
• 78. Wang N, Chen M, Wang T. Liposomes used as a vaccine adjuvant-delivery system: from basics to clinical immunization. J. Control Rel. 303, 130–150 (2019). •• Nanoliposomes as delivery systems for cancer immunotherapy
  Medline CASGoogle Scholar
• 79. Allison AC, Gregoriadis G. Liposomes as immunological adjuvants. In: Lymphocytes, Macrophages, and Cancer. Mathé GFlorentin ISimmler M-C (Eds). Springer Berlin-Heidelberg, Berlin/Heidelberg, Germany, 58–64 (1976).
  Google Scholar
• 80. Beiu C, Giurcaneanu C, Grumezescu AM et al. Nanosystems for improved targeted therapies in melanoma. J. Clin. Med. 9(2), 318 (2020).
  CASGoogle Scholar
• 81. Perez SA, Anastasopoulou EA, Tzonis P et al. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a Phase I trial. Cancer Immunol. Immunother. 62(10), 1599–1608 (2013).
  Medline CASGoogle Scholar
• 82. Bode C, Zhao G, Steinhagen F et al. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 10(4), 499–511 (2011).
  Medline CASGoogle Scholar
• 83. Barati N, Nikpoor AR, Razazan A et al. Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer. Immunol. Lett. 190, 108–117 (2017).
  Medline CASGoogle Scholar
• 84. Barati N, Nikpoor AR, Mosaffa F et al. AE36 HER2/neu-derived peptide linked to positively charged liposomes with CpG-ODN as an effective therapeutic and prophylactic vaccine for breast cancer. J. Drug Deliv. Sci. Technol. 67, 102904 (2021).
  Google Scholar
• 85. Shariat S, Badiee A, Jalali SA et al. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Lett. 355(1), 54–60 (2014). • Liposomes for prophylactic vaccine formulation for breast cancer.
  Medline CASGoogle Scholar
• 86. Jalali SA, Sankian M, Tavakkol-Afshari J, Jaafari MR. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomed.: Nanotechnol. Biol. Med. 8(5), 692–701 (2012).
  CASGoogle Scholar
• 87. Farzad N, Barati N, Momtazi-Borojeni AA et al. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Artif. Cells Nanomed. Biotechnol. 47(1), 665–673 (2019).
  MedlineGoogle Scholar
• 88. Naghibi L, Yazdani M, Momtazi-Borojeni AA et al. Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLOS ONE 15(12), e0243550 (2020).
  Medline CASGoogle Scholar
• 89. Mansourian M, Badiee A, Jalali SA et al. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunol. Lett. 162(1 Pt A), 87–93 (2014).
  Medline CASGoogle Scholar
• 90. Razazan A, Behravan J, Arab A et al. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model. PLOS ONE 12(10), e0185099 (2017).
  MedlineGoogle Scholar
• 91. Vacchelli E, Galluzzi L, Eggermont A et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1(6), 894–907 (2012).
  MedlineGoogle Scholar
• 92. Alexander J, Sidney J, Southwood S et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1(9), 751–761 (1994).
  Medline CASGoogle Scholar
• 93. Zamani P, Navashenaq JG, Nikpoor AR et al. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. J. Control Rel. 303, 223–236 (2019).
  Medline CASGoogle Scholar
• 94. Shen L, Li J, Liu Q et al. Local blockade of interleukin 10 and C-X-C motif chemokine ligand 12 with nano-delivery promotes antitumor response in murine cancers. ACS Nano 12(10), 9830–9841 (2018).
  Medline CASGoogle Scholar
• 95. Beltrán-Gracia E, López-Camacho A, Higuera-Ciapara I et al. Nanomedicine review: clinical developments in liposomal applications. Cancer Nanotechnol. 10(1), 11 (2019).
  CASGoogle Scholar
• 96. Shi Y. Clinical translation of nanomedicine and biomaterials for cancer immunotherapy: progress and perspectives. Adv. Ther. 3(9), 1900215 (2020).
  CASGoogle Scholar
• 97. Soliman HH. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Oncol. Targets Ther. 10, 101–112 (2017).
  Medline CASGoogle Scholar
• 98. Schmid P, Adams S, Rugo HS et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379(22), 2108–2121 (2018).
  Medline CASGoogle Scholar
• 99. Shroff RT, Kennedy EB, Bachini M et al. Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline. J. Clin. Oncol. 37(12), 1015–1027 (2019).
  MedlineGoogle Scholar
• 100. Badwaik HR, Kumari L, Nakhate K, Verma VS, Sakure K. Chapter 13: Phytoconstituent plumbagin: chemical, biotechnological and pharmaceutical aspects. In: Studies in Natural Products Chemistry. Atta Ur R (Ed.). Elsevier, Amsterdam, Netherlands, 415–460 (2019).
  Google Scholar
• 101. Wang S, Hu X, Wei W, Ma G. Transformable vesicles for cancer immunotherapy. Adv. Drug Deliv. Rev. 179, 113905 (2021).
  Medline CASGoogle Scholar
• 102. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int. J. Pharm. 172(1), 33–70 (1998).
  CASGoogle Scholar
• 103. Brewer JM, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology 75(4), 570–575 (1992).
  Medline CASGoogle Scholar
• 104. Brewer JM, Alexander J. Studies on the adjuvant activity of non-ionic surfactant vesicles: adjuvant-driven IgG2a production independent of MHC control. Vaccine 12(7), 613–619 (1994).
  Medline CASGoogle Scholar
• 105. Jain S, Singh P, Mishra V, Vyas SP. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B. Immunol. Lett. 101(1), 41–49 (2005).
  Medline CASGoogle Scholar
• 106. Jain S, Vyas SP. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J. Liposome Res. 16(4), 331–345 (2006).
  Medline CASGoogle Scholar
• 107. Vyas SP, Singh RP, Jain S et al. Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int. J. Pharm. 296(1–2), 80–86 (2005).
  Medline CASGoogle Scholar
• 108. Jain S, Sharma RK, Vyas SP. Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in-vitro and in-vivo characterization. J. Pharm. Pharmacol. 58(3), 303–310 (2006).
  Medline CASGoogle Scholar
• 109. Pamornpathomkul B, Niyomtham N, Yingyongnarongkul BE et al. Cationic niosomes for enhanced skin immunization of plasmid DNA-encoding ovalbumin via hollow microneedles. AAPS PharmSciTech 19(1), 481–488 (2018).
  Medline CASGoogle Scholar
• 110. Rathee J, Kanwar R, Kaushik D et al. Niosomes as efficient drug delivery modules for encapsulation of Toll-like receptor 7 agonists and IDO-inhibitor. Appl. Surf. Sci. 505, 144078 (2020).
  CASGoogle Scholar
• 111. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm. 50(1), 161–177 (2000).
  Medline CASGoogle Scholar
• 112. Tekade RK, Maheshwari R, Tekade M, Chougule MB. Chapter 8: solid lipid nanoparticles for targeting and delivery of drugs and genes. In: Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes. Mishra VKesharwani PMohd Amin MCIIyer A (Eds). Academic Press, MA, USA, 256–286 (2017).
  Google Scholar
• 113. Talluri SV, Kuppusamy G, Karri VV et al. Lipid-based nanocarriers for breast cancer treatment – comprehensive review. Drug Deliv. 23(4), 1291–1305 (2016).
  Medline CASGoogle Scholar
• 114. Rajpoot K. Solid lipid nanoparticles: a promising nanomaterial in drug delivery. Curr. Pharm. Des. 25(37), 3943–3959 (2019).
  Medline CASGoogle Scholar
• 115. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59(6), 478–490 (2007).
  Medline CASGoogle Scholar
• 116. Stelzner JJ, Behrens M, Behrens SE, Mäder K. Squalene containing solid lipid nanoparticles, a promising adjuvant system for yeast vaccines. Vaccine 36(17), 2314–2320 (2018).
  Medline CASGoogle Scholar
• 117. Limeres MJ, Suñé-Pou M, Prieto-Sánchez S et al. Development and characterization of an improved formulation of cholesteryl oleate-loaded cationic solid-lipid nanoparticles as an efficient non-viral gene delivery system. Colloids Surf B Biointerfaces 184, 110533 (2019).
  Medline CASGoogle Scholar
• 118. Mishra H, Mishra D, Mishra PK et al. Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis B surface antigen for vaccination using subcutaneous route. J. Pharm. Pharm. Sci. 13(4), 495–509 (2010).
  Medline CASGoogle Scholar
• 119. Saljoughian N, Zahedifard F, Doroud D et al. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Parasite Immunol 35(12), 397–408 (2013).
  Medline CASGoogle Scholar
• 120. Liu Y, Tiruthani K, Wang M et al. Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer. Nanoscale Horiz 6(4), 319–329 (2021).
  Medline CASGoogle Scholar
• 121. Deng C, Jia M, Wei G et al. Inducing optimal antitumor immune response through coadministering iRGD with pirarubicin loaded nanostructured lipid carriers for breast cancer therapy. Mol. Pharm. 14(1), 296–309 (2017).
  Medline CASGoogle Scholar
• 122. Ganta S, Talekar M, Singh A et al. Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech 15(3), 694–708 (2014).
  Medline CASGoogle Scholar
• 123. Verma P, Meher JG, Asthana S et al. Perspectives of nanoemulsion assisted oral delivery of docetaxel for improved chemotherapy of cancer. Drug Deliv. 23(2), 479–488 (2016).
  Medline CASGoogle Scholar
• 124. Maeda H, Wu J, Sawa T et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Rel. 65(1–2), 271–284 (2000).
  Medline CASGoogle Scholar
• 125. Praveen Kumar G, Divya A. Nanoemulsion based targeting in cancer therapeutics. Med. Chem. 5(5), 272–284 (2015).
  Google Scholar
• 126. Liu C, Lai H, Chen T. Boosting natural killer cell-based cancer immunotherapy with selenocystine/transforming growth factor-beta inhibitor-encapsulated nanoemulsion. ACS Nano 14(9), 11067–11082 (2020).
  Medline CASGoogle Scholar
• 127. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24(1), 1–16 (2007).
  Medline CASGoogle Scholar
• 128. Trubetskoy VS. Polymeric micelles as carriers of diagnostic agents. Adv. Drug Deliv. Rev. 37(1–3), 81–88 (1999).
  Medline CASGoogle Scholar
• 129. Wei X, Liu L, Li X et al. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy. J. Control Rel. 313, 42–53 (2019).
  Medline CASGoogle Scholar
• 130. Wang Y, Luan Z, Zhao C et al. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy. Eur. J. Pharm. Sci. 142, 105136 (2020).
  Medline CASGoogle Scholar
• 131. Zhou L, Hou B, Wang D et al. Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer. Nano Lett. 20(6), 4393–4402 (2020).
  Medline CASGoogle Scholar
• 132. Nair PR. Delivering combination chemotherapies and targeting oncogenic pathways via polymeric drug delivery systems. Polymers 11(4), 630 (2019).
  Google Scholar
• 133. Wong KH, Lu A, Chen X, Yang Z. Natural ingredient-based polymeric nanoparticles for cancer treatment. Molecules 25(16), 3620 (2020).
  Google Scholar
• 134. Cafaggi S, Russo E, Stefani R et al. Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin-alginate complex. J. Control Rel 121(1–2), 110–123 (2007).
  Medline CASGoogle Scholar
• 135. Castro F, Pinto ML, Pereira CL et al. Chitosan/γ-PGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer. Biomaterials 257, 120218 (2020).
  Medline CASGoogle Scholar
• 136. Kim KS, Han JH, Choi SH et al. Cationic nanoparticle-mediated activation of natural killer cells for effective cancer immunotherapy. ACS Appl. Mater. Interfaces 12(51), 56731–56740 (2020).
  Medline CASGoogle Scholar
• 137. Masjedi A, Ahmadi A, Ghani S et al. Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy. Nanomedicine 29, 102240 (2020).
  Medline CASGoogle Scholar
• 138. Masjedi A, Ahmadi A, Atyabi F et al. Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression. Int. J. Biol. Macromol 149, 487–500 (2020).
  Medline CASGoogle Scholar
• 139. Dey A, Manna S, Kumar S et al. Immunostimulatory effect of chitosan conjugated green copper oxide nanoparticles in tumor immunotherapy. Cytokine 127, 154958 (2020).
  Medline CASGoogle Scholar
• 140. Bastaki S, Aravindhan S, Ahmadpour Saheb N et al. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice. Life Sci. 266, 118847 (2021).
  Medline CASGoogle Scholar
• 141. Liu L, Wang Y, Guo X et al. A biomimetic polymer magnetic nanocarrier polarizing tumor-associated macrophages for potentiating immunotherapy. Small 16(38), e2003543 (2020).
  Medline CASGoogle Scholar
• 142. Kakwere H, Zhang H, Ingham ES et al. Systemic immunotherapy with micellar resiquimod-polymer conjugates triggers a robust antitumor response in a breast cancer model. Adv. Healthc. Mater. 10(10), e2100008 (2021).
  Medline CASGoogle Scholar
• 143. Chen C, Guo Q, Fu H et al. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis. Biomaterials 275, 120988 (2021).
  Medline CASGoogle Scholar
• 144. Kresge ACT, Leonowicz ME, Roth WJ et al. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 359(6397), 710–712 (1992).
  CASGoogle Scholar
• 145. Chen YP, Xu L, Tang TW et al. STING Activator c-di-GMP-loaded mesoporous silica nanoparticles enhance immunotherapy against breast cancer. ACS Appl. Mater. Interfaces 12(51), 56741–56752 (2020).
  Medline CASGoogle Scholar
• 146. Becicka WM, Bielecki PA, Lorkowski ME et al. The effect of PEGylation on the efficacy and uptake of an immunostimulatory nanoparticle in the tumor immune microenvironment. Nanoscale Adv. 3(17), 4961–4972 (2021).
  Medline CASGoogle Scholar
• 147. Xu JL, Jin B, Ren ZH et al. Chemotherapy plus erlotinib versus chemotherapy alone for treating advanced non-small cell lung cancer: a meta-analysis. PLOS ONE 10(7), e0131278 (2015).
  Medline CASGoogle Scholar
• 148. Gurunathan S, Kang MH, Qasim M, Kim JH. Nanoparticle-mediated combination therapy: two-in-one approach for cancer. Int. J. Mol. Sci. 19(10), 3264 (2018).
  Google Scholar
• 149. Liu R, An Y, Jia W et al. Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer. J. Control. Rel. 321, 589–601 (2020).
  Medline CASGoogle Scholar
• 150. Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 20(3), e175–e186 (2019).
  Medline CASGoogle Scholar
• 151. Lang T, Liu Y, Zheng Z et al. Cocktail strategy based on spatio-temporally controlled nano device improves therapy of breast cancer. Adv. Mater. 31(5), e1806202 (2019).
  MedlineGoogle Scholar
• 152. Zhang W, Zhang CC, Wang XY et al. Light-responsive core-shell nanoplatform for bimodal imaging-guided photothermal therapy-primed cancer immunotherapy. ACS Appl. Mater. Interfaces 12(43), 48420–48431 (2020).
  Medline CASGoogle Scholar
• 153. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771–782 (2008).
  Medline CASGoogle Scholar
• 154. Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16(2), 121–126 (2016).
  Medline CASGoogle Scholar
• 155. Chemocare. Atezolizumab (Tecentriq). https://chemocare.com/chemotherapy/drug-info/atezolizumab.aspx
  Google Scholar
• 156. Immunotherapy for Breast Cancer. How is immunotherapy for breast cancer changing the outlook for patients? Cancer Research Institute. www.cancerresearch.org/en-us/immunotherapy/cancer-types/breast-cancer
  Google Scholar
• 157. Targeted Antibodies: mAbs, ADCs, BiTEs, and More. Monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. Cancer Resaerch Institute www.cancerresearch.org/en-us/immunotherapy/treatment-types/targeted-antibodies
  Google Scholar
• 158. Barar J, Omidi Y. Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies. Bioimpacts 5(2), 65–69 (2015).
  MedlineGoogle Scholar
• 159. Fathi M, Abdolahinia ED, Barar J, Omidi Y. Smart stimuli-responsive biopolymeric nanomedicines for targeted therapy of solid tumors. Nanomedicine 15(22), 2171–2200 (2020).
  CASGoogle Scholar
• 160. Dolatkhah M, Hashemzadeh N, Barar J et al. Graphene-based multifunctional nanosystems for simultaneous detection and treatment of breast cancer. Colloids Surf. B Biointerfaces 193, 111104 (2020).
  Medline CASGoogle Scholar
• 161. Liu L, Wang Y, Miao L et al. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. Mol. Ther. 26(1), 45–55 (2018).
  Medline CASGoogle Scholar
• 162. Lei J, Wang H, Zhu D et al. Combined effects of avasimibe immunotherapy, doxorubicin chemotherapy, and metal-organic frameworks nanoparticles on breast cancer. J. Cell Physiol. 235(5), 4814–4823 (2020). • Combination therapy.
  Medline CASGoogle Scholar
• 163. Yuan SJ, Xu YH, Wang C et al. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer. J. Nanobiotechnology 17(1), 110 (2019).
  MedlineGoogle Scholar
• 164. Wei J, Long Y, Guo R et al. Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer. Acta Pharm. Sinica B 9(4), 819–831 (2019).
  MedlineGoogle Scholar
• 165. Liu X, Feng Z, Wang C et al. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses. Biomaterials 230, 119649 (2020).
  Medline CASGoogle Scholar
• 166. Liu Y, Qiao L, Zhang S et al. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Acta Biomater. 66, 310–324 (2018).
  Medline CASGoogle Scholar
• 167. Wan Z, Sun J, Xu J et al. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. Acta Biomater. 90, 300–313 (2019).
  Medline CASGoogle Scholar
• 168. Sun JJ, Chen YC, Huang YX et al. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier. Acta Pharmacol. Sinica 38(6), 823–834 (2017).
  Medline CASGoogle Scholar
• 169. Qin T, Xu X, Zhang Z et al. Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer. Nanotechnology 31(36), 365101 (2020).
  Medline CASGoogle Scholar
• 170. Zhang LX, Sun XM, Xu ZP, Liu RT. Development of multifunctional clay-based nanomedicine for elimination of primary invasive breast cancer and prevention of its lung metastasis and distant inoculation. ACS Appl. Mater. Interfaces 11(39), 35566–35576 (2019).
  Medline CASGoogle Scholar
• 171. Liu J, Ai X, Cabral H, Liu J, Huang Y, Mi P. Tumor hypoxia-activated combinatorial nanomedicine triggers systemic antitumor immunity to effectively eradicate advanced breast cancer. Biomaterials 273, 120847 (2021).
  Medline CASGoogle Scholar
• 172. Kumar P, Srivastava R. IR 820 dye encapsulated in polycaprolactone glycol chitosan: Poloxamer blend nanoparticles for photo immunotherapy for breast cancer. Mater. Sci. Eng. C Mater. Biol. Appl. 57, 321–327 (2015).
  Medline CASGoogle Scholar
• 173. Cheng Y, Chen Q, Guo Z et al. An intelligent biomimetic nanoplatform for holistic treatment of metastatic triple-negative breast cancer via photothermal ablation and immune remodeling. ACS Nano 14(11), 15161–15181 (2020).
  Medline CASGoogle Scholar
• 174. Zhang J, Zhang D, Li Q et al. Task-specific design of immune-augmented nanoplatform to enable high-efficiency tumor immunotherapy. ACS Appl. Mater. Interfaces 11(46), 42904–42916 (2019).
  Medline CASGoogle Scholar
• 175. Lan Y, Liang Q, Sun Y et al. Codelivered chemotherapeutic doxorubicin via a dual-functional immunostimulatory polymeric prodrug for breast cancer immunochemotherapy. ACS Appl. Mater. Interfaces 12(28), 31904–31921 (2020).
  Medline CASGoogle Scholar
• 176. Luo L, Zhu C, Yin H et al. Laser immunotherapy in combination with perdurable pd-1 blocking for the treatment of metastatic tumors. ACS Nano 12(8), 7647–7662 (2018).
  Medline CASGoogle Scholar
• 177. Wang X, Li J, Kawazoe N, Chen G. Photothermal ablation of cancer cells by albumin-modified gold nanorods and activation of dendritic cells. Materials 12(1), 31 (2018).
  MedlineGoogle Scholar
• 178. Wang L, Wang M, Zhou B et al. PEGylated reduced-graphene oxide hybridized with Fe(3)O(4) nanoparticles for cancer photothermal-immunotherapy. J. Mater. Chem. B 7(46), 7406–7414 (2019).
  MedlineGoogle Scholar
• 179. Wang R, He Z, Cai P et al. Surface-functionalized modified copper sulfide nanoparticles enhance checkpoint blockade tumor immunotherapy by photothermal therapy and antigen Capturing. ACS Appl. Mater. Interfaces 11(15), 13964–13972 (2019).
  Medline CASGoogle Scholar
• 180. Liu H, Hu Y, Sun Y et al. Co-delivery of bee venom melittin and a photosensitizer with an organic-inorganic hybrid nanocarrier for photodynamic therapy and immunotherapy. ACS Nano 13(11), 12638–12652 (2019).
  Medline CASGoogle Scholar
• 181. Yang G, Xu L, Xu J et al. Smart nanoreactors for ph-responsive tumor homing, mitochondria-targeting, and enhanced photodynamic-immunotherapy of cancer. Nano Lett. 18(4), 2475–2484 (2018).
  Medline CASGoogle Scholar
• 182. Yu X, Gao D, Gao L et al. Inhibiting metastasis and preventing tumor relapse by triggering host immunity with tumor-targeted photodynamic therapy using photosensitizer-loaded functional nanographenes. ACS Nano 11(10), 10147–10158 (2017).
  Medline CASGoogle Scholar
• 183. Duan X, Chan C, Guo N, Han W, Weichselbaum RR, Lin W. Photodynamic therapy mediated by nontoxic core-shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and antimetastatic effect on breast cancer. J. Am. Chem. Soc. 138(51), 16686–16695 (2016).
  Medline CASGoogle Scholar
• 184. Marrache S, Tundup S, Harn DA, Dhar S. Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. ACS Nano 7(8), 7392–7402 (2013).
  Medline CASGoogle Scholar
• 185. Wang M, Song J, Zhou F et al. NIR-triggered phototherapy and immunotherapy via an antigen-capturing nanoplatform for metastatic cancer treatment. Adv Sci 6(10), 1802157 (2019).
  Google Scholar
• 186. Fatima SW, Khare SK. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy. J. Control. Rel. 341, 555–565 (2022).
  Medline CASGoogle Scholar
• 187. Howard D, Garcia-Parra J, Healey GD et al. Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus 6(6), 20160054 (2016).
  MedlineGoogle Scholar
• 188. Iyer U, Kadambi VJ. Antibody drug conjugates – Trojan horses in the war on cancer. J. Pharmacol. Toxicol. Methods 64(3), 207–212 (2011).
  Medline CASGoogle Scholar
• 189. De Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr. Opin. Immunol. 40, 14–23 (2016).
  MedlineGoogle Scholar
• 190. Takahashi I, Takahashi K, Ichimura M et al. Duocarmycin A, a new antitumor antibiotic from Streptomyces. J. Antibiot. (Tokyo) 41(12), 1915–1917 (1988).
  Medline CASGoogle Scholar
• 191. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100(4), 572–579 (2009).
  Medline CASGoogle Scholar
• 192. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 453(1), 198–214 (2013).
  Medline CASGoogle Scholar